Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.

Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, Lindsay R, Mitlak BH

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA18 Aug 2004Cited by 185 (Europe PMC)

PMID15322742DOI10.1007/s00198-004-1713-3PepBankPUB-15322742

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studyEfficacy outcome
In men with osteoporosis who could receive follow-up antiresorptive therapy, combined teriparatide groups had a nonsignificant 51% lower vertebral fracture risk versus placebo.
In plain wordsIn men, teriparatide groups had a nonsignificant 51% lower vertebral fracture risk than placebo during follow-up that allowed antiresorptive treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeVertebral fracture risk
Study
n = 279
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Vertebral fracture risk reduction
51%
combined teriparatide groups versus placebo
Source sentences
Summary
In the combined teriparatide treated groups vs placebo, the risk of vertebral fracture was reduced 51% (nonsignificant, p=0.07).
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this manuscript is to report on bone mineral density and vertebral fracture incidence during a 42-month observation period, from the baseline of the previously reported treatment study in men [1] through 30 months of posttreatment follow-up.
Summary · context
Three hundred fifty-five men who were treated with once-daily self-injections of either placebo or 20 or 40 microg of teriparatide participated in the follow-up study.
Report a problemFND-1532274206
02HumanObservational studyEfficacy outcome
In men with osteoporosis who could receive follow-up antiresorptive therapy, combined teriparatide groups had 83% fewer moderate or severe vertebral fractures versus placebo.
In plain wordsIn men, teriparatide groups had 83% fewer moderate or severe vertebral fractures than placebo during follow-up that allowed antiresorptive treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseModerate or severe vertebral fracture
Study
n = 279
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Moderate or severe vertebral fracture reduction
83%
combined teriparatide groups versus placebo
Source sentences
Summary
The incidence of moderate or severe fractures was significantly reduced by 83% (p=0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
In the combined teriparatide treated groups vs placebo, the risk of vertebral fracture was reduced 51% (nonsignificant, p=0.07).
Summary · context
The purpose of this manuscript is to report on bone mineral density and vertebral fracture incidence during a 42-month observation period, from the baseline of the previously reported treatment study in men [1] through 30 months of posttreatment follow-up.
Summary · context
Three hundred fifty-five men who were treated with once-daily self-injections of either placebo or 20 or 40 microg of teriparatide participated in the follow-up study.
Report a problemFND-1532274207
03HumanObservational studyEfficacy outcome
In men with osteoporosis who could receive follow-up antiresorptive therapy, incident vertebral fractures occurred in 5.4% of men assigned to teriparatide 20 microg versus 11.7% assigned to placebo.
In plain wordsIn men assigned teriparatide 20 microg, 5.4% had new vertebral fractures versus 11.7% with placebo during follow-up that allowed antiresorptive treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedIncident vertebral fracture
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg dailyAs given in this study (human).
Measurements
Incident vertebral fracture
5.4%
teriparatide 20 microg
Incident vertebral fracture
11.7%
placebo
Source sentences
Summary
Of these men, 11.7% assigned to placebo, 5.4% treated with teriparatide 20 microg, and 6.0% treated with teriparatide 40 microg had an incident vertebral fracture.
3 context sentences(design, population, supporting numbers)
Summary · context
Lateral thoracic lumbar radiographs obtained at baseline and 18 months after discontinuation of teriparatide were available for 279 men.
Summary · context
The purpose of this manuscript is to report on bone mineral density and vertebral fracture incidence during a 42-month observation period, from the baseline of the previously reported treatment study in men [1] through 30 months of posttreatment follow-up.
Summary · context
Three hundred fifty-five men who were treated with once-daily self-injections of either placebo or 20 or 40 microg of teriparatide participated in the follow-up study.
Report a problemFND-1532274204
04HumanObservational studyEfficacy outcome
In men with osteoporosis who could receive follow-up antiresorptive therapy, incident vertebral fractures occurred in 6.0% of men assigned to teriparatide 40 microg versus 11.7% assigned to placebo.
In plain wordsIn men assigned teriparatide 40 microg, 6.0% had new vertebral fractures versus 11.7% with placebo during follow-up that allowed antiresorptive treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedIncident vertebral fracture
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg dailyAs given in this study (human).
Measurements
Incident vertebral fracture
6%
teriparatide 40 microg
Incident vertebral fracture
11.7%
placebo
Source sentences
Summary
Of these men, 11.7% assigned to placebo, 5.4% treated with teriparatide 20 microg, and 6.0% treated with teriparatide 40 microg had an incident vertebral fracture.
3 context sentences(design, population, supporting numbers)
Summary · context
Lateral thoracic lumbar radiographs obtained at baseline and 18 months after discontinuation of teriparatide were available for 279 men.
Summary · context
The purpose of this manuscript is to report on bone mineral density and vertebral fracture incidence during a 42-month observation period, from the baseline of the previously reported treatment study in men [1] through 30 months of posttreatment follow-up.
Summary · context
Three hundred fifty-five men who were treated with once-daily self-injections of either placebo or 20 or 40 microg of teriparatide participated in the follow-up study.
Report a problemFND-1532274205

Studies that did not test the peptide alone3

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

05HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In men with osteoporosis who could receive follow-up antiresorptive therapy, BMD gradually decreased after teriparatide discontinuation.
In plain wordsIn men, bone density decreased after teriparatide stopped during follow-up that allowed antiresorptive treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBMD after discontinuation
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Bone mineral density gradually decreased following discontinuation of teriparatide therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this manuscript is to report on bone mineral density and vertebral fracture incidence during a 42-month observation period, from the baseline of the previously reported treatment study in men [1] through 30 months of posttreatment follow-up.
Summary · context
Three hundred fifty-five men who were treated with once-daily self-injections of either placebo or 20 or 40 microg of teriparatide participated in the follow-up study.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1532274201
06HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In men with osteoporosis who could receive follow-up antiresorptive therapy, lumbar spine BMD remained above baseline after 30 months of follow-up.
In plain wordsIn men, spine bone density remained above baseline after teriparatide stopped, with antiresorptive treatment allowed.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD after discontinuation
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
However, the lumbar spine and total hip values remained significantly higher than baseline after 30 months of follow-up (p< or =0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this manuscript is to report on bone mineral density and vertebral fracture incidence during a 42-month observation period, from the baseline of the previously reported treatment study in men [1] through 30 months of posttreatment follow-up.
Summary · context
Three hundred fifty-five men who were treated with once-daily self-injections of either placebo or 20 or 40 microg of teriparatide participated in the follow-up study.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1532274202
07HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In men with osteoporosis who could receive follow-up antiresorptive therapy, total hip BMD remained above baseline after 30 months of follow-up.
In plain wordsIn men, hip bone density remained above baseline after teriparatide stopped, with antiresorptive treatment allowed.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD after discontinuation
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
However, the lumbar spine and total hip values remained significantly higher than baseline after 30 months of follow-up (p< or =0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this manuscript is to report on bone mineral density and vertebral fracture incidence during a 42-month observation period, from the baseline of the previously reported treatment study in men [1] through 30 months of posttreatment follow-up.
Summary · context
Three hundred fifty-five men who were treated with once-daily self-injections of either placebo or 20 or 40 microg of teriparatide participated in the follow-up study.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1532274203

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.